Stock Rich List
#2053 on the rich list of 14,644 insiders

Jeremy Green

10% owner at Zymeworks; Director at Absci; Director at Shattuck Labs. Based in New York, New York.

$67.4M
in disclosed stock, −$165K (−0.24%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
2053rd of 14,644
Companies held
1
Largest holding
ABSI, 100.0% of total
Latest SEC filing
Jul 22, 2026
Listed but not counted
$407M

What the $67.4M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Absci ABSI
Common Stock
Indirectly (see filing footnote)8,262,136$8.16$67.4M100.0%Form 4, Jun 12, 2024

Share counts are the amounts Jeremy Green reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on Jeremy Green's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
Zymeworks ZYME
Common Stock, par value $0.00001 per share
Through Redmile Group, LLC
Held by a company or fund the insider manages
6,075,918$26.86$163M—Form 4/A, Oct 13, 2022
Zymeworks ZYME
Common Stock, par value $0.00001 per share
Through Redmile Group, LLC
Held by a company or fund the insider manages
6,045,437$26.86$162M—Form 3, Oct 13, 2022
Shattuck Labs STTK
Common Stock
Indirectly (see filing footnote)
Held by a company or fund the insider manages
5,615,489$4.55$25.6M—Form 4, Mar 28, 2024
Shattuck Labs STTK
Common Stock, par value $0.0001 per share
Indirectly (see filing footnote)
Held by a company or fund the insider manages
5,539,724$4.55$25.2M—Form 4, Dec 4, 2024
Fate Therapeutics FATE
Common Stock
Indirectly (see filing footnote)
Held by a company or fund the insider manages
13,180,388$1.01$13.3M—Form 4, Dec 26, 2023
Fate Therapeutics FATE
Common Stock
Indirectly (see filing footnote)
Held by a company or fund the insider manages
12,884,277$1.01$13.0M—Form 4, Dec 20, 2024
Atara Biotherapeutics ATRA
Common Stock
Through Redmile Group, LLC
Held by a company or fund the insider manages
636,852$6.34$4.0M—Form 4, Jul 22, 2026

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
2050Horacio D. Rozanski
CEO, Booz Allen Hamilton Holding. Mclean, VA
$67.6M−$1.2M (−1.70%)
2051Matthew S. Bromberg
President and CEO, Unity Software. San Francisco, CA
$67.5M−$3.3M (−4.60%)
2052Joth Ricci
CEO, Dutch Bros. Grants Pass, OR
$67.5M−$2.6M (−3.72%)
2053Jeremy Green
10% owner, Zymeworks. New York, NY
$67.4M−$165K (−0.24%)
2054Murry Gerber
Director, BlackRock. New York, NY
$67.4M−$1.3M (−1.85%)
2055Russell Craig Ellwanger
Chief Executive Officer, Tower Semiconductor. Bedford, WY
$67.3M−$2.5M (−3.62%)
2056Richard M. Beyer
Director, Micron Technology. Boise, ID
$67.3M−$1.4M (−2.10%)

Other Zymeworks insiders

All ZYME insiders

Questions

How much stock does Jeremy Green own?

Jeremy Green holds $67,419,030 in listed stock based on SEC filings and current prices, mostly Absci (ABSI). That ranks 2053rd on the Stock Rich List.

Is this Jeremy Green's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.